ATOPIC DERMATITIS (AD)

This study is testing a new biologic drug called Stapokibart, given as a shot, for adults with moderate-to-severe atopic dermatitis (eczema). The trial will enroll 1000 people to see if the drug is safe and helps control the condition. It is an open-label study, meaning everyone …

This early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…

This study tests an experimental drug called BFB759, a lab-made antibody that blocks several inflammatory signals at once. Researchers want to see if it can reduce redness, swelling, and itching in adults with moderate-to-severe eczema that hasn't improved with creams. About 225 …

This early-stage trial tests whether a new drug called GS101 works like the approved eczema treatment Dupixent. Researchers will give a single shot to 294 healthy adults in China and compare how the drug moves through the body, its safety, and immune response. The goal is to see …

This early-stage trial is testing a new drug called ZL-1503 for safety and how the body processes it. It involves 84 participants: first healthy volunteers, then people with moderate to severe atopic dermatitis (eczema). The study is 'double-blind' and 'placebo-controlled,' meani…

This study looks at the long-term safety and effectiveness of a drug called CM512 for people with atopic dermatitis (eczema). It is for patients who have already finished a previous CM512 study. The main goal is to track any side effects over time.

This study looks at whether CeraVe moisturizing cream can help maintain skin hydration and prevent eczema from coming back in people with mild to moderate atopic dermatitis. Participants first use a steroid cream to clear their skin, then apply either CeraVe or a standard emollie…

This study tests whether a partially hydrolyzed formula with added synbiotics can prevent atopic dermatitis (eczema) in 400 infants at high risk for allergies. Babies are enrolled within 14 days of birth and followed for skin barrier function and eczema development. The goal is t…

This study tests whether a new oral drug called ENV-294 can safely reduce eczema severity in adults with moderate-to-severe atopic dermatitis. Sixty participants will take either ENV-294 or a placebo pill daily for 12 weeks. Researchers will measure changes in skin symptoms and t…

This early-stage trial is testing a new injectable drug called ARQ-234 in healthy volunteers and people with moderate to severe eczema. The main goals are to check safety and how the body processes the drug, while also looking for early signs that it might improve eczema symptoms…

This early-stage study tests an experimental oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. The main goal is to check if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through t…

This pilot study tests whether a cream made with glycomacropeptide, a milk protein, can reduce eczema symptoms in children aged 2 to 12 with mild atopic dermatitis. Twenty children will apply either the glycomacropeptide cream or a standard moisturizer twice daily for four weeks.…

This international study observes how people with atopic dermatitis (eczema) access healthcare, what treatments they receive, and how the disease affects their daily lives. Researchers will collect data from routine medical records of about 9,600 participants across multiple coun…

This study tests whether a special microscope (reflectance confocal microscopy) can detect skin changes in people with moderate-to-severe eczema who are taking tralokinumab. The drug blocks a protein involved in inflammation and is already known to help eczema. Researchers want t…

This pilot study is testing whether Botox injections can change how skin cells behave in people with mild-to-moderate eczema. Eight adults will receive small doses of Botox into their eczema patches. Researchers will measure changes in eczema severity and analyze skin biopsies to…

This study looks at whether babies born with certain self-reactive antibodies are more likely to develop eczema. Researchers will test umbilical cord blood from 500 newborns—some with a family history of allergies or eczema, some without—and follow them for two years. The goal is…